Int J Angiol 2021; 30(01): 076-082
DOI: 10.1055/s-0041-1723977
Review Article

Therapeutic Options for Left Main, Left Main Equivalent, and Three-Vessel Disease

1   Department of Cardiology, Detroit Medical Center, Heart Hospital, Wayne State University, Detroit, Michigan
,
Bayoan Ramos-Parra
1   Department of Cardiology, Detroit Medical Center, Heart Hospital, Wayne State University, Detroit, Michigan
,
Amir Kaki
1   Department of Cardiology, Detroit Medical Center, Heart Hospital, Wayne State University, Detroit, Michigan
2   Department of Cardiology, Ascension St. John Hospital, Detroit, Michigan
› Author Affiliations
Funding None.

Abstract

Patients with left main, left main equivalent, and three-vessel coronary artery disease (CAD) represent an overlapping spectrum of patients with advanced CAD that is associated with an adverse prognosis. Guideline-directed medical therapy is a necessary but often insufficient treatment option, as such patients frequently need mechanical revascularization by either coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI). In patients with advanced CAD presenting with acute myocardial infarction, PCI, of course, is the preferred treatment option. For stable patients with advanced CAD, CABG surgery remains the standard of care. However, observations from the SYNergy between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery (SYNTAX) trial suggest that PCI may be a useful alternative in patients with three-vessel disease with a low SYNTAX score as well as in patients with left main disease and a low or intermediate SYNTAX score. In the subset of patients with diabetes mellitus, the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease trial unequivocally demonstrated the superiority of CABG surgery in improving outcomes. The findings of the recently published Everolimus-Eluting Stent System versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization and Nordic–Baltic–British Left Main Revascularization study trials point to a favorable role for PCI in certain low-to-moderate risk patients with left main stem disease.

Authorship

All authors had access to the data and a role in writing the manuscript.




Publication History

Article published online:
12 February 2021

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Holm NR, Mäkikallio T, Lindsay MM. et al; NOBLE investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 2020; 395 (10219): 191-199
  • 2 Serruys PW, Morice MC, Kappetein AP. et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360 (10) 961-972
  • 3 Stone GW, Kappetein AP, Sabik JF. et al; EXCEL Trial Investigators. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 2019; 381 (19) 1820-1830
  • 4 Ragosta M, Dee S, Sarembock IJ, Lipson LC, Gimple LW, Powers ER. Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv 2006; 68 (03) 357-362
  • 5 Caracciolo EA, Davis KB, Sopko G. et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91 (09) 2335-2344
  • 6 Myers WO, Gersh BJ, Fisher LD. et al. Medical versus early surgical therapy in patients with triple-vessel disease and mild angina pectoris: a CASS registry study of survival. Ann Thorac Surg 1987; 44 (05) 471-486
  • 7 Boden WE, O'Rourke RA, Teo KK. et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356 (15) 1503-1516
  • 8 Ramadan R, Boden WE, Kinlay S. Management of left main coronary artery disease. J Am Heart Assoc 2018; 7 (07) e008151
  • 9 Grundy SM, Stone NJ, Bailey AL. et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73 (24) e285-e350
  • 10 Eckel RH, Jakicic JM, Ard JD. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (25 Pt B): 2960-2984
  • 11 GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343 (8906): 1115-1122
  • 12 Bonaca MP, Bhatt DL, Cohen M. et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
  • 13 Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg 1968; 5 (04) 334-339
  • 14 Braunwald E. Effects of coronary-artery bypass grafting on survival. Implications of the randomized coronary-artery surgery study. N Engl J Med 1983; 309 (19) 1181-1184
  • 15 Yusuf S, Zucker D, Peduzzi P. et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344 (8922): 563-570
  • 16 Loop FD, Lytle BW, Cosgrove DM. et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314 (01) 1-6
  • 17 Head SJ, Milojevic M, Taggart DP, Puskas JD. Current practice of state-of-the-art surgical coronary revascularization. Circulation 2017; 136 (14) 1331-1345
  • 18 Farina P, Gaudino MFL, Taggart DP. The eternal debate with a consistent answer: CABG vs PCI. Semin Thorac Cardiovasc Surg 2020; 32 (01) 14-20
  • 19 Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978; 1 (8058): 263
  • 20 O'Keefe Jr JH, Hartzler GO, Rutherford BD. et al. Left main coronary angioplasty: early and late results of 127 acute and elective procedures. Am J Cardiol 1989; 64 (03) 144-147
  • 21 Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335 (04) 217-225
  • 22 Sigwart U. The Stent Story: how it all started…. Eur Heart J 2017; 38 (28) 2171-2172
  • 23 Ragosta M. Left main coronary artery disease: importance, diagnosis, assessment, and management. Curr Probl Cardiol 2015; 40 (03) 93-126
  • 24 Serruys PW, Ong ATL, van Herwerden LA. et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46 (04) 575-581
  • 25 Rodriguez AE, Baldi J, Fernández Pereira C. et al; ERACI II Investigators. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005; 46 (04) 582-588
  • 26 Hueb W, Lopes NH, Gersh BJ. et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115 (09) 1082-1089
  • 27 Russo FD, Rao SV. Coronary stents. In: Kern MJ, Seto AH. eds. SCAI Interventional Cardiology Review. Philadelphia: Wolters Kluwer; 2018: 187-195
  • 28 Sianos G, Morel MA, Kappetein AP. et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1 (02) 219-227
  • 29 SYNTAX score calculator. SYNTAX working-group, launched May 19, 2009 at: http://www.syntaxscore.com. Accessed September 10, 2020
  • 30 Serruys PW, Onuma Y, Garg S. et al. Assessment of the SYNTAX score in the SYNTAX study. EuroIntervention 2009; 5 (01) 50-56
  • 31 Farooq V, Garg S, Serruys PW. Individualized assessment for percutaneous or surgical revascularization. In: Topol EJ, Teirstein PS. eds. Textbook of Interventional Cardiology. Philadelphia: Elsevier; 2016: 1-31
  • 32 Windecker S, Kolh P, Alfonso F. et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35 (37) 2541-2619
  • 33 Fihn SD, Blankenship JC, Alexander KP. et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64 (18) 1929-1949
  • 34 Mohr FW, Morice MC, Kappetein AP. et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381 (9867): 629-638
  • 35 Thuijs DJFM, Kappetein AP, Serruys PW. et al; SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019; 394 (10206): 1325-1334
  • 36 Taggart DP. CABG or stents in coronary artery disease: end of the debate?. Lancet 2013; 381 (9867): 605-607
  • 37 Farkouh ME, Domanski M, Sleeper LA. et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367 (25) 2375-2384
  • 38 Esper RB, Farkouh ME, Ribeiro EE. et al. SYNTAX score in patients with diabetes undergoing coronary revascularization in the FREEDOM trial. J Am Coll Cardiol 2018; 72 (23 Pt A): 2826-2837
  • 39 Fedak PWM, Bhatt DL, Verma S. Coronary bypass surgery for diabetes and multivessel disease: forget the SYNTAX. J Am Coll Cardiol 2018; 72 (23 Pt A): 2838-2840
  • 40 Neumann FJ, Sousa-Uva M, Ahlsson A. et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
  • 41 Ragosta M. Revascularization of Left Main Disease: Do we EXCEL at Stenting?. Or Is It More NOBLE to Treat With Surgery? Expert Analysis. American College of Cardiology; 2020 . Accessed September 20, 2020 at: https://www.acc.org/latest-in-cardiology/articles/2017/03/08/08/05/revascularization-of-left-main-disease
  • 42 Taggart DP, Gaudino M. PCI or CABG for left main coronary artery disease. N Engl J Med 2020; 383 (03) 290
  • 43 Lee MS, Manthripragada G. Left mainstem Intervention. In: Kern MJ, Seto AH. eds. SCAI Interventional Cardiology Review. Philadelphia: Wolters Kluwer; 2018: 187-195
  • 44 STS Short-Term Risk Calculator. The Society of Thoracic Surgeons, launched November 15, 2018 at: http://riskcalc.sts.org/stswebriskcalc/calculate. Accessed September 10, 2020
  • 45 Ranucci M, Castelvecchio S, Conte M. et al. The easier, the better: age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery. J Thorac Cardiovasc Surg 2011; 142 (03) 581-586
  • 46 Garg S, Sarno G, Garcia-Garcia HM. et al; ARTS-II Investigators. A new tool for the risk stratification of patients with complex coronary artery disease: the clinical SYNTAX score. Circ Cardiovasc Interv 2010; 3 (04) 317-326
  • 47 Kinnaird T, Gallagher S, Anderson R. et al. Are higher operator volumes for unprotected left main stem percutaneous coronary intervention associated with improved patient outcomes? A survival analysis of 6724 procedures from the British Cardiovascular Intervention Society National Database. Circ Cardiovasc Interv 2020; 13 (06) e008782
  • 48 Xu B, Redfors B, Yang Y. et al. Impact of operator experience and volume on outcomes after left main coronary artery percutaneous coronary intervention. JACC Cardiovasc Interv 2016; 9 (20) 2086-2093
  • 49 Glazier JJ, Kaki A. The Impella device: historical background, clinical applications and future directions. Int J Angiol 2019; 28 (02) 118-123
  • 50 Collet C, Capodanno D, Onuma Y. et al. Left main coronary artery disease: pathophysiology, diagnosis, and treatment. Nat Rev Cardiol 2018; 15 (06) 321-331